Last month, I wrote a Medscape commentary titled "Advice for the New USPSTF" that made several suggestions about how to get the Task Force's work back on track after an 18-month hiatus since its last meeting. I advised that the 8 new members receive a grounding in the USPSTF's rigorous methods for making recommendations, that the Agency for Healthcare Research and Quality (AHRQ) be supplied with resources and staff to support the work, that the Task Force set priorities for updating recommendations free from political interference, and that old and new members resist the temptation to "assign certain services stronger ratings than warranted by the evidence so that patients can more easily access them."
I didn't expect anyone in the leadership of the Department of Health and Human Services, much less Secretary Kennedy, to heed my advice. Still, it was discouraging to read Maggie Astor's New York Times story earlier this week, based on interviews with 15 former USPSTF members and AHRQ employees, outlining how this administration has systematically dismantled its evidence synthesis infrastructure and asserted political control over every aspect of its operations.
Historically, USPSTF meetings have been invitation-only and not open to the public. As much as I've written about the Task Force over the years, the last meeting I attended was in 2010, my last as an AHRQ medical officer. The afternoon prior to the Nov. 19-20 meeting, AHRQ announced that portions would be open to the public on Zoom. Since I had administrative time on Thursday morning, I decided to tune in.
It's important to emphasize that Task Force meetings, while critical to discussing and finalizing recommendations, represent the culmination of many hours of behind-the-scenes work that takes place during conference calls between meetings. I heard from one of the current USPSTF members that they continued much of this work despite not being allowed to meet from March 2025 until now. But it was immediately clear that there had been little interaction between the recently appointed members and the so-called "legacy" members selected previously through the traditional apolitical process.
Not only had the new members evidently skipped reading the methods manual, they seemed to have not been briefed at all on the 3 recommendations slated to be finalized: screening for cervical cancer, screening for unhealthy alcohol use, and counseling to prevent perinatal depression. (Normally this would be a discredit to the AHRQ staff, but remember, they have all been fired or forced to resign.) One new member complained that differences between the USPSTF's screening guidelines and those of medical groups are confusing to clinicians. As a practicing family physician, I empathize, but his proposed solution - having the Task Force instead adopt, wholesale, the other group's consensus guideline - showed a total misunderstanding of the purpose of the USPSTF. Medical groups have lots of reasons to make recommendations that go beyond the evidence; the Task Force is supposed to only recommend interventions that literature shows unequivocally improve outcomes for patients.
I give the legacy members credit for pushing back during this meeting. They criticized a political oversight process that had stripped out all references to race and sexual minorities from a statement when these characteristics were relevant to many scientific studies. When the AHRQ director (a molecular pathologist and lawyer whose official biography suggests hasn't practiced medicine since residency) pontificated that making decisions about patients based solely on their race is unethical, a Task Force member countered that this was a straw man, and no one in the room was advocating any such thing. Several members questioned AHRQ's unprecedented decision to invite intellectually and financially conflicted subspecialists to present on chronic kidney disease, colorectal cancer, and lung cancer. (To be clear, subspecialists have been involved in the development of USPSTF recommendations long before any were appointed to the Task Force, but evidence is typically presented by neutral systematic reviewers.)
The Times published a follow-up story with additional details worth reading (though oddly, it shows a stock photo of Secretary Kennedy, who did not attend). I suppose it could have been worse, but what I saw at this week's meeting did little to reassure me that the current incarnation of the USPSTF will be an asset to primary care, particularly after 3 more legacy members rotate off at the end of this year.






